June 2012 Editor's Picks: Products from EMD Millipore and Meissner Filtration Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

June 2012 Editor's Picks: Products from EMD Millipore and Meissner Filtration Products

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

EMD Millipore
Single-use bioreactor is designed for process development or pilot-scale cell culture

EMD Millipore’s Mobius CellReady 50-L single-use, stirred tank bioreactor is designed for process development and pilot-scale mammalian cell culture. The rigid base and top panel design of the bioreactor process container enables simple, reliable, and robust one-way installation. Mobius SensorReady technology allows the user to configure process monitoring at the point of use and enables integration of new sensor technologies. The system is available as a turnkey solution complete with Finesse automation or as modules that can be integrated with the customer’s platform of choice.


Meissner Filtration Products
Containers support disposable biocontainer assemblies

Meissner Filtration Products’ QuaDrum containers for Meissner’s TepoFlex 3D biocontainer assemblies have a square design rather than the industry standard cylindrical design.  The design makes efficient use of floor space, and can be used with a stainless steel dolly for intra-facility transport. The reusable, polyethylene containers are chemically resistant and can be sanitized. Slotted lids offer access to tubing and filters or solid lids completely cover the assembly.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Equipment and Processing Report,
Click here